Thermo Fisher Scientific (MA, USA) are set to acquire Qiagen (Hilden, Germany), a provider of molecular diagnostics and sample preparation technologies, in an $11.5 billion transaction.
Frontage expand bioanalytical capabilities to support drug development, biomarker testing and high throughput sample management
The Pennsylvania-based CRO, Frontage Holdings Corporation (PA, USA), has completed the expansion of its bioanalytical laboratories in Exton (PA, USA). The expansion is designed to enhance the group’s bioanalytical capabilities.
Agilent Technologies (CA, USA) have teamed up with the Indian Institute of Technology Delhi (India) to provide an incubator site for bioanalytical science.
Analytical laboratory instrument and software provider, Waters Corporation (MA, USA) have officially announced plans to acquire Swiss-based laboratory automation technology innovator Andrew Alliance (Geneva, Switzerland).
Thermo Fisher Scientific (MA, USA) and Agilent Technologies (CA, USA) renew their commitment to the Instrument Control Exchange Program, which aims to improve workflow efficiency by allowing users to select hardware and software that most appropriately meet their application needs.
Charles River Laboratories (MA, USA) are set to expand into the rapidly growing cell therapy market through the acquisition of human-derived cellular product producer, HemaCare Corporation (CA, USA).
Frontage (PA, USA), a CRO with operations in the USA and China has announced their acquisition of BRI Biopharmaceutical Research, Inc. (BC, CA). The acquisition sees Frontage expanding their geographic foothold into Canada and the West Coast of North America.
Advancing novel biomarker identification: Thermo Fisher Scientific collaborate with Owlstone Medical
Thermo Fisher Scientific (MA, USA) have announced a collaborative partnership with Owlstone Medical (Cambridge, UK). The partnership will work towards the advancement of early cancer and disease diagnosis through the discovery and validation of novel biomarkers.
Thermo Fisher Scientific (MA, USA) have announced a new molecular quality control panel. The panel could provide researchers with increased confidence when performing BCR-ABL assays.
Drug discovery and development company, Evotec (Hamburg, Germany), enter a new collaboration agreement with Asia’s largest pharmaceutical company, Takeda (Tokyo, Japan), which promises to discover clinical candidates across multiple therapeutic areas.